H&H国际控股（01112）：业绩拐点兑现，经营持续向上

Investment Rating - The report maintains a "Buy" rating for H&H International Holdings (01112.HK) [4][7] Core Views - The company is experiencing a performance turnaround with continuous operational improvement, highlighted by a low double-digit revenue growth in 2025 and a strong double-digit growth in infant nutrition and care products [1][4] - Adjusted comparable EBITDA is expected to grow by 2% to 6% year-on-year, with an adjusted net profit growth forecast of 15% to 25% [1][4] Summary by Relevant Sections ANC (Adult Nutrition Category) - The company has increased its market share in mainland China, achieving low double-digit growth in 2025, while other expanding markets saw strong double-digit growth [2] - Innovative product categories such as heart health and anti-aging are experiencing robust growth, with Swisse Plus and Little Swisse continuing to expand [2] - The e-commerce market for health products in China is projected to grow by approximately 10% year-on-year, with Swisse outperforming the industry growth rate [2] BNC (Baby Nutrition Category) - The infant nutrition and care segment achieved strong double-digit growth, particularly in infant formula, which significantly outpaced the industry growth rate in mainland China [3] - The company’s strategy of expanding customer acquisition through dedicated infant stores and social media platforms has shown significant results [3] - The infant probiotic and nutritional supplements segment saw low single-digit growth, driven by new product launches and accelerated growth in dedicated stores and online channels [3] PNC (Pet Nutrition Category) - The pet nutrition and care segment achieved high single-digit growth in 2025, with expectations for accelerated growth following product structure optimization and channel adjustments [3] Financial Projections - The company is projected to achieve net profits of 422 million, 584 million, and 714 million RMB for the years 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 886.3%, 38.2%, and 22.3% [4][6] - The expected adjusted net profit for 2025 is between 620 million and 680 million RMB, corresponding to a price-to-earnings ratio (PE) of 12-13x [4]